Acarix receives order from the first freestanding Emergency Room in the US
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the CADScor System has been added to the diagnostic tools av...
NOTICE OF ANNUAL GENERAL MEETING IN ACARIX AB
The shareholders of Acarix AB, reg. no. 559009-0667 (the "Company"), are hereby invited to the annual general meeting on Tuesday 14 May...
KALLELSE TILL ÅRSSTÄMMA I ACARIX AB
Aktieägarna i Acarix AB, org.nr 559009-0667 ("Bolaget"), kallas härmed till årsstämma tisdagen den 14 maj 2024 kl....
Acarix announces the initiation of the first US-based clinical workflow evaluation study
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the initiation of the first US-based clinical study to colle...
Acarix inleder klinisk utvärderingsstudie hos University of California
Acarix, ledande inom avancerad akustikbaserad hjärtdiagnostik, tillkännager idag uppstarten av den första kliniska studi...
Acarix adopts new growth-focused business model and provides outlook update as part of our ongoing strategic review
Acarix, a leader in advanced acoustic- and algorithm-based cardiac diagnostics, announces the adoption of a new innovative usage-based ...
Acarix antar ny tillväxtfokuserad affärsmodell och ger en uppdatering av strategiska och finansiella mål
Acarix, ledande aktör inom akustik- och algoritmbaserad hjärtdiagnostik, tillkännager idag införandet av en ny inno...
New Health Economic Analysis Presented at ACC Highlights The Acarix CADScor System’s Cost-Effectiveness
Acarix, a leader in acoustic-based Cardiac Diagnostics, is pleased to announce the results from a 2024 American College of Cardiology (...
Ny hälsoekonomisk analys presenterad på ACC styrker kostnadseffektiviteten i Acarix CADScor System
Acarix, ledande aktör inom akustiskbaserad hjärtdiagnostik, tillkännager idag resultaten från en presentation p&ar...
Acarix has submitted application for cross-trading at OTCQB in the US
New York, New York, April 5, 2024 – Acarix, a leader in advanced acoustic-based cardiac diagnostics announces the submission of a...
Acarix lämnar in ansökan om handel av bolagets aktie på OTCQB-marknaden i USA
New York, New York, 5 april 2024 – Acarix, ledande inom akustisk- och algoritmbaserad hjärtdiagnostik, meddelar idag inl&aum...
Acarix announces the outcome of the exercise of warrants of series 2024:U1 (TO2)
The Board of directors of Acarix AB ("Acarix" or the "Company") today announces the outcome of the exercise period for warrants of seri...